Clinical Characteristics, Treatment Outcomes, and Prognosis in Patients with MKIs-associated Hand-foot Skin Reaction: a Retrospective Study

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2023 Jun 5

PMID 37273007

Authors

Liumei Shou

Jialu Chen

Tianyu Shao

Yao Zhang

Shuya Zhao

Shuyi Chen

Qijin Shu

Affiliations

Soon will be listed here.

Abstract

Background: Multikinase inhibitors (MKIs) treatment has been proven as a powerful strategy in cancer therapy. However, it is greatly hampered by its common adverse effect known as hand-foot skin reaction (HFSR), especially in patients with moderate-to-severe HFSR.

Objective: To investigate the clinical characteristics, histopathological features, treatment response, and bio-indicators of HFSR.

Methods: We retrospectively reviewed the medical records of 102 patients with moderate-to-severe HFSR resulting from MKIs therapy.

Results: The median time to development of moderate-to-severe HFSR was 18 days, which would be significantly affected by the type of MKIs and the history of HFSR. Notably, we found that HFSR was classified into three consecutive stages: erythematous lesion, yellow hyperkeratotic lesion with surrounding erythema, and hyperkeratotic lesion. Inflammation was observed in the first two stages of HFSR, but disappeared in the third stage; in contrast, the hyperkeratosis gradually became thicker from stage one to stage three. Moreover, topical medications were demonstrated as an effective therapy for HFSR, among which, the topical steroids and urea ointment treatment response rate was 37.14%, the Shouzu Ning Decoction (SND) treatment response rate was 65%, and the SND in combination with urea ointment treatment response rate was 75%, meanwhile, systemic therapies did not improve the therapeutic efficacy of topical medications alone. In addition, the serum levels of HMGB1 were found to be a potential indicator for tracking the healing process as well as predicting the prognosis of HFSR.

Conclusion: This study revealed the potential factors affecting the development of HFSR, evaluated the therapeutic response towards different strategies for treating HFSR, and identified a potential prognostic indicator of HFSR.

References

Yang J, Yan J, Liu B . Targeting VEGF/VEGFR to Modulate Antitumor Immunity. Front Immunol. 2018; 9:978. PMC: 5943566. DOI: 10.3389/fimmu.2018.00978. View

Liu G, Chen T, Ding Z, Wang Y, Wei Y, Wei X . Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment. Cell Prolif. 2021; 54(4):e13009. PMC: 8016646. DOI: 10.1111/cpr.13009. View

Jayson G, Kerbel R, Ellis L, Harris A . Antiangiogenic therapy in oncology: current status and future directions. Lancet. 2016; 388(10043):518-29. DOI: 10.1016/S0140-6736(15)01088-0. View

Ding F, Liu B, Wang Y . Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients. J Am Acad Dermatol. 2019; 83(3):788-796. DOI: 10.1016/j.jaad.2019.04.021. View

Freites-Martinez A, Santana N, Arias-Santiago S, Viera A . Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed). 2020; 112(1):90-92. DOI: 10.1016/j.ad.2019.05.009. View

Chanprapaph K, Rutnin S, Vachiramon V . Multikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management. Am J Clin Dermatol. 2016; 17(4):387-402. DOI: 10.1007/s40257-016-0197-1. View

McLellan B, Ciardiello F, Lacouture M, Segaert S, Van Cutsem E . Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol. 2015; 26(10):2017-26. PMC: 4576906. DOI: 10.1093/annonc/mdv244. View

Ai L, Xu Z, Yang B, He Q, Luo P . Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management. Expert Rev Clin Pharmacol. 2019; 12(12):1121-1127. DOI: 10.1080/17512433.2019.1689122. View

Anderson R, Keating K, Doll H, Camacho F . The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for Oncology. Oncologist. 2015; 20(7):831-8. PMC: 4492225. DOI: 10.1634/theoncologist.2014-0219. View

10.

Lacouture M, Sibaud V, Gerber P, van den Hurk C, Fernandez-Penas P, Santini D . Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines. Ann Oncol. 2020; 32(2):157-170. DOI: 10.1016/j.annonc.2020.11.005. View

11.

Luo P, Yan H, Chen X, Zhang Y, Zhao Z, Cao J . s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand-foot skin reaction that can be reversed by nicotinamide. Cell Res. 2020; 30(9):779-793. PMC: 7608389. DOI: 10.1038/s41422-020-0309-6. View

12.

Perucci L, Sugimoto M, Gomes K, Dusse L, Teixeira M, Sousa L . Annexin A1 and specialized proresolving lipid mediators: promoting resolution as a therapeutic strategy in human inflammatory diseases. Expert Opin Ther Targets. 2017; 21(9):879-896. DOI: 10.1080/14728222.2017.1364363. View

13.

Wang S, Zhang Y . HMGB1 in inflammation and cancer. J Hematol Oncol. 2020; 13(1):116. PMC: 7443612. DOI: 10.1186/s13045-020-00950-x. View

14.

Yang Q, Zang H, Xing T, Zhang S, Li C, Zhang Y . Gypenoside XLIX protects against acute kidney injury by suppressing IGFBP7/IGF1R-mediated programmed cell death and inflammation. Phytomedicine. 2021; 85:153541. DOI: 10.1016/j.phymed.2021.153541. View

15.

Shinohara N, Nonomura N, Eto M, Kimura G, Minami H, Tokunaga S . A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma. Ann Oncol. 2013; 25(2):472-6. DOI: 10.1093/annonc/mdt541. View

16.

Melosky B, Lim H, Davies J, Gill S, Kollmannsberger C, Ho M . A phase II trial of the effect of perindopril on hand-foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC. Cancer Chemother Pharmacol. 2018; 83(3):411-417. PMC: 6394486. DOI: 10.1007/s00280-018-3738-x. View

17.

Jatoi A, Ou F, Ahn D, Zemla T, Le-Rademacher J, Boland P . Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. Oncologist. 2021; 26(7):610-618. PMC: 8265366. DOI: 10.1002/onco.13730. View

18.

Lee Y, Jung Y, Kim J, Cho S, Kim D, Kim M . Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study. Eur J Cancer. 2020; 140:19-27. DOI: 10.1016/j.ejca.2020.09.012. View

19.

Ren Z, Zhu K, Kang H, Lu M, Qu Z, Lu L . Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015; 33(8):894-900. DOI: 10.1200/JCO.2013.52.9651. View

20.

Shou L, Shao T, Zhao F, Chen S, Chen Q, Shu Q . The Efficacy and Safety of the Shouzu Ning Decoction Treatment for Multi-Kinase Inhibitors-Associated Severe Hand-Foot Skin Reaction. Cancer Manag Res. 2021; 13:45-53. PMC: 7800444. DOI: 10.2147/CMAR.S285002. View